Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9447853 | 0.85 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL16972355 | 0.85 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL626316 | 0.85 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL626315 | 0.85 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL8598647 | 0.84 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL21447936 | 0.84 | AAK1 (0.39) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL27041525 | 0.83 | MEN1 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL27041531 | 0.83 | MEN1 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL25185689 | 0.83 | MMP13 (0.36) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL27041514 | 0.83 | MMP13 (0.36) | MMP13AAK1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250137-A1 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| EP-2373597-A2 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063403-A2 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250137-A1 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION | ODC1, OTC, ARG1 | MMP13 4086/4885AAK1 3663/4885MEN1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.